Hematological Parameters Predict Severity of Acute Pancreatitis
By LabMedica International staff writers Posted on 23 Jul 2018 |

Image: A blood smear shows size heterogeneity of peripheral red blood cells, known as anisocytosis (Photo courtesy of Dr. Jay Park, MD).
Acute pancreatitis (AP) is an acute inflammation of the pancreatic parenchyma induced by activated pancreatic enzymes due to multiple causes. Current severity scores include multiple variables and some of them are only complete within 48 hours of admission.
Until now, no single serum marker is able to predict severity or mortality in AP at admission. Red cell distribution width (RDW) is a routine parameter of the complete blood count test, described as simple, easy, inexpensive and quantitative that measures the size heterogeneity of peripheral red blood cell (RBC), known as anisocytosis.
Gastroenterologists at the University of Coimbra (Coimbra, Portugal) conducted a retrospective case-control study from January 2014 to December 2016, including a total of 312 consecutive admissions with AP. Ninety-one patients with severe AP were identified during the study period (cases) and were compared with patients with mild AP (controls), in the 1:1 proportion.
Biochemical and arterial blood gas (ABG) tests at admission were also registered, including white blood cells (WBC) count, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, platelet count, blood urea nitrogen (BUN), creatinine, international normalized ratio (INR), albumin, lactate dehydrogenase (LDH), serum glucose, hemoglobin, hematocrit, serum amylase, C-reactive protein at 0 hour (CRP0h), CRP at 24 hours (CRP24h), arterial lactate, arterial partial pressure of oxygen, D-dimers, total serum calcium (TSC), RDW at 0 hour (RDW0h), RDW at 24 hour (RDW24h). Additionally, RDW0h-to-TSC ratio and RDW0h-to-platelets ratio were evaluated.
The team found that there was a significant association of severe AP with high BUN (26.6 ± 17.1 versus 19.4 ± 8.8); serum glucose (168.0 ± 72.6 versus 130.9 ± 35.5); RDW0h (14.6 ± 1.3 versus 12.7 ± 0.5); RDW24h (14.3 ± 1.9 versus 12.8 ± 0.5); and RDW0h-to-TSC ratio (1.8 ± 0.4 versus 1.3 ± 0.1). The overall mortality rate was 8.8% (16/182), all cases associated with severe AP, corresponding to a mortality rate of 17.6% (16/91) in the severe AP group. Relatively to mortality in AP and as verified for AP severity, RDW at 0 hours and 24 hours post-admission were the best predictors for mortality in AP, followed by RDW0h-to-TSC ratio.
The authors concluded that RDW is a simple routine parameter, available at admission. The AP cohort showed that RDW0h of greater than 13.0 and RDW0h-to-total serum calcium ratio greater than 1.4 were excellent predictors for severity and RDW0h greater than 14.0 and RDW0h-to-total serum calcium ratio of greater than 1.7 were very-good predictors for mortality, being superior to conventional prognostic scoring systems. The study was published on July 5, 2018, in the journal BMC Gastroenterology.
Related Links:
University of Coimbra
Until now, no single serum marker is able to predict severity or mortality in AP at admission. Red cell distribution width (RDW) is a routine parameter of the complete blood count test, described as simple, easy, inexpensive and quantitative that measures the size heterogeneity of peripheral red blood cell (RBC), known as anisocytosis.
Gastroenterologists at the University of Coimbra (Coimbra, Portugal) conducted a retrospective case-control study from January 2014 to December 2016, including a total of 312 consecutive admissions with AP. Ninety-one patients with severe AP were identified during the study period (cases) and were compared with patients with mild AP (controls), in the 1:1 proportion.
Biochemical and arterial blood gas (ABG) tests at admission were also registered, including white blood cells (WBC) count, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, platelet count, blood urea nitrogen (BUN), creatinine, international normalized ratio (INR), albumin, lactate dehydrogenase (LDH), serum glucose, hemoglobin, hematocrit, serum amylase, C-reactive protein at 0 hour (CRP0h), CRP at 24 hours (CRP24h), arterial lactate, arterial partial pressure of oxygen, D-dimers, total serum calcium (TSC), RDW at 0 hour (RDW0h), RDW at 24 hour (RDW24h). Additionally, RDW0h-to-TSC ratio and RDW0h-to-platelets ratio were evaluated.
The team found that there was a significant association of severe AP with high BUN (26.6 ± 17.1 versus 19.4 ± 8.8); serum glucose (168.0 ± 72.6 versus 130.9 ± 35.5); RDW0h (14.6 ± 1.3 versus 12.7 ± 0.5); RDW24h (14.3 ± 1.9 versus 12.8 ± 0.5); and RDW0h-to-TSC ratio (1.8 ± 0.4 versus 1.3 ± 0.1). The overall mortality rate was 8.8% (16/182), all cases associated with severe AP, corresponding to a mortality rate of 17.6% (16/91) in the severe AP group. Relatively to mortality in AP and as verified for AP severity, RDW at 0 hours and 24 hours post-admission were the best predictors for mortality in AP, followed by RDW0h-to-TSC ratio.
The authors concluded that RDW is a simple routine parameter, available at admission. The AP cohort showed that RDW0h of greater than 13.0 and RDW0h-to-total serum calcium ratio greater than 1.4 were excellent predictors for severity and RDW0h greater than 14.0 and RDW0h-to-total serum calcium ratio of greater than 1.7 were very-good predictors for mortality, being superior to conventional prognostic scoring systems. The study was published on July 5, 2018, in the journal BMC Gastroenterology.
Related Links:
University of Coimbra
Latest Clinical Chem. News
- AI-Powered Blood Test Accurately Detects Ovarian Cancer
- Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
- Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
- First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read moreMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreMolecular Diagnostics
view channel
POC Diagnostic Platform Combines Immunoassay and Molecular Testing
An innovative diagnostic platform offers superior sensitivity across all sample types, including blood, compared to existing rapid tests, while maintaining a low-cost, user-friendly design.... Read more
Single Blood Test Could Detect Different Types of Cancer at Early Stages
Currently, reliable screening for only a few types of cancer is available, such as those affecting the breast, bowel, cervix (neck of the womb), and lung for individuals at high risk. While these screenings... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Blood Test Detects Up to Five Infectious Diseases at POC
Researchers have developed a prototype flow-through assay capable of detecting up to five different infections, with results that can be quickly analyzed and transmitted via a specialized smartphone app.... Read more
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Qiagen Acquires NGS Analysis Software Company Genoox
QIAGEN (Venlo, the Netherlands) has signed a definitive agreement to acquire Genoox (Tel Aviv, Israel), a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and... Read more
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more